The Trump administration revealed its latest pharmaceutical agreement on Thursday, reaching new deals with drug companies Novo Nordisk and Eli Lilly to offer their GLP-1 products at reduced rates under the Most Favored Nation (MFN) policy.

According to senior officials, both companies have consented to sell their injectable GLP-1 medications—Novo Nordisk’s Wegovy and Lilly’s Zepbound—at an initial monthly price of $245 for those enrolled in Medicare and Medicaid, as well as users of the soon-to-be-launched TrumpRX platform, anticipated early next year.

Additionally, oral GLP-1 medications will be available through these channels at a starting price of $149 per month. However, a senior official clarified that this pricing applies only to GLP-1 tablets currently under FDA review for obesity approval and does not include Rybelsus, the sole FDA-approved oral GLP-1 at present.